Last reviewed · How we verify
PDC-APB
At a glance
| Generic name | PDC-APB |
|---|---|
| Also known as | Active |
| Sponsor | Hapten Sciences, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB (PHASE1)
- A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PDC-APB CI brief — competitive landscape report
- PDC-APB updates RSS · CI watch RSS
- Hapten Sciences, Inc. portfolio CI